Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.
Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up.
复制标题
DOI：
10.14309/ctg.0000000000000298
复制
发表时间：
2021-02-15
影响因子：
3.6
通讯作者：
SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group
中科院分区：
文献类型：
--
作者：
Bravo F;Macpherson JA;Slack E;Patuto N;Cahenzli J;McCoy KD;Macpherson AJ;Juillerat P;SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group
开发生物标志物以指导炎症性肠病（IBD）患者的抗肿瘤坏死因子（TNF）药物治疗是一项未满足的需求。我们开发了一种体外血液测定法，用于预测抗TNF α药物英夫利昔单抗（IFX）治疗患者的长期结局。IBD患者根据全血中粒细胞表面的L-选择素（CD 62 L）脱落进行分类。在药物施用之前和之后通过流式细胞术定量CD 62 L脱落。从2012年6月至2017年8月收集的盲态IFX管理的临床数据旨在验证该测试的长期预测价值。在33例IBD患者（17例克罗恩病和5例溃疡性结肠炎）中，根据体外试验，22例预测为功能应答者（PFR），11例预测为无应答者（NR）。研究开始五年后，72%的PFR仍接受IFX治疗（NR组为27%; P < 0.05），接受IFX治疗的中位时间分别为45个月和12个月（P = 0.019）。发生了35起内外科事件，至首次事件的中位时间分别为3个月和30个月（P = 0.023）。我们的测定是长期使用IFX的最佳独立预测因子（P = 0.056）。一项基于测定的TNFα（CD 62 L脱落）功能性阻断体外试验为IBD患者IFX的持久使用提供了一个极好的长期（3-5年）独立预测因子。测试患者可以个性化决策，以显着降低成本和不良事件和并发症的风险。
The development of biomarkers to guide management of anti–tumor necrosis factor (TNF) agents in patients with inflammatory bowel disease (IBD) is an unmet need. We developed an in vitro blood assay to predict patient long-term outcome with the anti-TNFα agent infliximab (IFX). Patients with IBD were classified according to the shedding of an L-selectin (CD62L) from the surface of their granulocytes in whole blood. CD62L shedding was quantified by flow cytometry before and after drug administration. A clinical data collection from June 2012 to August 2017 with blinded IFX management was aimed at validating the long-term predictive value of this test. Among 33 patients with IBD (17 Crohn's disease and 5 ulcerative colitis), 22 were predicted functional responders (PFR) and 11 were predicted as nonresponders (NR) according to the in vitro test. Five years after study initiation, 72% of PFR were still treated with IFX (vs 27% in the NR group; P < 0.05), with a median time spent under IFX of 45 vs 12 months (P = 0.019), respectively. Thirty-five medicosurgical events occurred with a median time to first event of 3 vs 30 months (P = 0.023), respectively. Our assay was the best independent predictor of staying long term on IFX (P = 0.056). An assay-based in vitro test for functional blockade of TNFα (CD62L shedding) provides an excellent long-term (at 3–5 years) independent predictor of durable use of IFX in patients with IBD. Testing patients could personalize decision making to significantly reduce costs and risk of adverse events and complications.
登录
查看更多内容
影响因子：
29.4
作者：
Hanauer, SB;Sandborn, WJ;Pollack, P
通讯作者：
Pollack, P
影响因子：
3.2
作者：
Fasanmade, Adedigbo A.;Adedokun, Omoniyi J.;Davis, Hugh M.
通讯作者：
Davis, Hugh M.
影响因子：
2.9
作者：
Fasanmade, Adedigbo A.;Adedokun, Omoniyi J.;Zhou, Honghui
通讯作者：
Zhou, Honghui
影响因子：
3.7
作者：
Erdoes, Gabor;Balmer, Maria L.;Book, Malte
通讯作者：
Book, Malte
DOI：
10.1155/2001/91831
发表时间：
2001
期刊：
DEVELOPMENTAL IMMUNOLOGY
影响因子：
--
作者：
Zhao, L C;Edgar, J B;Dailey, M O
通讯作者：
Dailey, M O